Background: As the use of immune checkpoint inhibitors in postoperative adjuvant chemotherapy for patients with programmed death-ligand 1 (PD-L1)-expressing lung cancer has been increasing, it is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback